About VRDCT
Biotech outcome markets, built from deep DeFi experience and a biotech background.
Trade the event itself
A stock bundles clinical progress, financing, commercial execution and broader market conditions. VRDCT is being built around a specified biotech catalyst: a defined YES / NO outcome, explicit evidence and USDC settlement.
That creates a different exposure from owning the company, with its own liquidity, basis and resolution risks.
Available today
Search clinical studies, drug programs, public biotech filings, FDA records and linked PubMed evidence. Save the records and searches that matter.
Open research10,000 virtual USDC to inspect buying, selling, inventory pricing, price impact and PnL.
Explore the sandboxNot launched. This website implies no live listing, funded liquidity or approved oracle configuration.
Read the mechanismOpposing traders can fund positions, while VLP is designed to provide capped liquidity. A live AMM still needs actual LP capital, operating sponsorship and reviewed release terms.
Specific rights
A root YES / NO complete set is designed around one unit of USDC backing. A winning claim pays under the final result; INVALID splits backing equally.
These claims grant no stock, private-company ownership, royalty or drug IP. Earlier-stage access and financing need their own evidence, rights and operating framework. No shared vault or yield product takes deposits here.